{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:30:49Z","timestamp":1792672249682,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s00415-005-0918-5","type":"journal-article","created":{"date-parts":[[2005,7,5]],"date-time":"2005-07-05T22:36:04Z","timestamp":1120602964000},"page":"753-764","source":"Crossref","is-referenced-by-count":96,"title":["Psychotic symptoms in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"252","author":[{"given":"Spiridon","family":"Papapetropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Mash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"918_CR1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, et al. (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry 16(5):528\u2013536","journal-title":"Int J Geriatr Psychiatry"},{"key":"918_CR2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummins JL, et al. (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595\u2013601","journal-title":"Arch Neurol"},{"key":"918_CR3","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual for Psychiatric Disorders (1987) Revised third edition, ed. American Psychiatric Association. Washington, DC"},{"key":"918_CR4","unstructured":"American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th edn. 1994, Washington DC"},{"key":"918_CR5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","volume":"55","author":"Arnulf","year":"2000","unstructured":"Arnulf I, Bonnet AM, Damier P, et al. (2000) Hallucinations, REM sleep, and Parkinson\u2019s disease: a medical hypothesis. Neurology 55(2):281\u2013288","journal-title":"Neurology"},{"key":"918_CR6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.52.1.1","volume":"52","author":"Baker","year":"1999","unstructured":"Baker MG (1999) Depression, psychosis and dementia in Parkinson\u2019s disease. Neurology 52(7 Suppl 3):S1","journal-title":"Neurology"},{"key":"918_CR7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1212\/01.WNL.0000036908.39696.FD","volume":"59","author":"Ballard","year":"2002","unstructured":"Ballard CG, Aarsland D, McKeith I, et al. (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59(11):1714\u20131720","journal-title":"Neurology"},{"key":"918_CR8","first-page":"S108","volume":"12","author":"Barclay","year":"1997","unstructured":"Barclay CL, Hildebrand K, Gray P, et al. (1997) Risk factors for the development of psychosis in Parkinson\u2019s disease. Mov Disord 12(Suppl 1):S108","journal-title":"Mov Disord"},{"key":"918_CR9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","volume":"70","author":"Barnes","year":"2001","unstructured":"Barnes J, David AS (2001) Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70(6):727\u2013733","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","volume":"25","author":"Bergman","year":"2002","unstructured":"Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease. Clin Neuropharmacol 25(2):107\u2013110","journal-title":"Clin Neuropharmacol"},{"key":"918_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.expneurol.2004.05.041","volume":"189","author":"Betarbet","year":"2004","unstructured":"Betarbet R, Greenamyre JT (2004) Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol 189(2):393\u2013403","journal-title":"Exp Neurol"},{"key":"918_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01663632","volume":"37","author":"Birkmayer","year":"1975","unstructured":"Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human postmortem findings). J Neural Transm 37(2):175\u2013182","journal-title":"J Neural Transm"},{"key":"918_CR13","unstructured":"Brandt J, Spencer M, Folstein MF (1988) The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav, pp 111\u2013117"},{"key":"918_CR14","first-page":"37","volume":"17","author":"Brink","year":"1983","unstructured":"Brink TL, Rose TL, Lum O (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37\u201349","journal-title":"J Psychiatr Res"},{"key":"918_CR15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"Bullock","year":"2002","unstructured":"Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series. Curr Med Res Opin 18(5):258\u2013264","journal-title":"Curr Med Res Opin"},{"key":"918_CR16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0891988704267466","volume":"17","author":"Burn","year":"2004","unstructured":"Burn DJ, Troster AI (2004) Neuropsychiatric complications of medical and surgical therapies for Parkinson\u2019s disease. J Geriatr Psychiatry Neurol 17(3):172\u2013180","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"918_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archneur.1970.00480270003001","volume":"23","author":"Celesia","year":"1970","unstructured":"Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23(3):193\u2013200","journal-title":"Arch Neurol"},{"key":"918_CR18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.51.2.526","volume":"51","author":"Comella","year":"1998","unstructured":"Comella CL, Nardine TM, Diederich NJ, et al. (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson\u2019s disease. Neurology 51(2):526\u2013529","journal-title":"Neurology"},{"key":"918_CR19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.410340514","volume":"34","author":"Comella","year":"1993","unstructured":"Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson\u2019s disease patients with treatment-induced hallucinations. Ann Neurol 34(5):710\u2013714","journal-title":"Ann Neurol"},{"key":"918_CR20","first-page":"New","volume":"Press","author":"Cummings","year":"1992","unstructured":"Cummings JL (1992) Neuropsychiatric complications of drug treatment of Parkinson\u2019s disease in Parkinson\u2019s Disease. In: Huber SJ, Cumming JL (eds) Neurobehavioral Aspects. Oxford University Press: New York, pp 313\u2013327","journal-title":"Oxford University"},{"key":"918_CR21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/jnnp.45.12.1161","volume":"45","author":"de Smet","year":"1982","unstructured":"de Smet Y, Ruberg M, Serdaru M, et al. (1982) Confusion, dementia and anticholinergics in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 45(12):1161\u20131164","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR22","first-page":"New","volume":"Press","author":"Cummings","year":"1992","unstructured":"Cummings JL (1992) Neuropsychiatric complications of drug treatment of Parkinson\u2019s disease in Parkinson\u2019s Disease. In: Huber SJ, Cumming JL (eds) Neurobehavioral Aspects.Oxford University Press: New York, pp 313\u2013327","journal-title":"Oxford University"},{"key":"918_CR23","doi-asserted-by":"crossref","unstructured":"Doe De Maindreville A, Fenelon G, Mahieux F (2004) Hallucinations in Parkinson\u2019s disease: A follow-up study. Mov Disord","DOI":"10.1002\/mds.20263"},{"key":"918_CR24","first-page":"195","volume":"264","author":"Dravid","year":"1983","unstructured":"Dravid AR (1983) Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effect of chronic hydergine treatment. Arch Int Pharmacodyn Ther 264(2):195\u2013202","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"918_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"Fabbrini","year":"2002","unstructured":"Fabbrini G, Barbanti P, Aurilia C, et al. (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci 23(1):41\u201343","journal-title":"Neurol Sci"},{"key":"918_CR26","unstructured":"Fahn S, Elton RL (1987) Members of the UPDRS development Committee, Unified Parkinson\u2019s disease rating scale, in Recent developments in Parkinson\u2019s disease. Macmillan healthcare information, pp 153\u2013163"},{"key":"918_CR27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, et al. (2000) Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733\u2013745","journal-title":"Brain"},{"key":"918_CR28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00415-002-0908-9","volume":"249","author":"Fenelon","year":"2002","unstructured":"Fenelon G, Thobois S, Bonnet AM, et al. (2002) Tactile hallucinations in Parkinson\u2019s disease. J Neurol 249(12):1699\u20131703","journal-title":"J Neurol"},{"key":"918_CR29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1099-1166(200003)15:3<280::AID-GPS108>3.0.CO;2-N","volume":"15","author":"Fergusson","year":"2000","unstructured":"Fergusson E, Howard R (2000) Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 15(3):280\u2013281","journal-title":"Int J Geriatr Psychiatry"},{"key":"918_CR30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","volume":"14","author":"Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH, Jacques C, et al. (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord 14(3):484\u2013487","journal-title":"Mov Disord"},{"key":"918_CR31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1531-8257(200005)15:3<579::AID-MDS1024>3.0.CO;2-0","volume":"15","author":"Fernandez","year":"2000","unstructured":"Fernandez HH, Lannon MC, Friedman JH, et al. (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord 15(3):579\u2013581","journal-title":"Mov Disord"},{"key":"918_CR32","first-page":"391","volume":"53","author":"Fischer","year":"1990","unstructured":"Fischer P, Danielczyk W, Simanyi M, et al. (1990) Dopaminergic psychosis in advanced Parkinson\u2019s disease. Adv Neurol 53:391\u2013397","journal-title":"Adv Neurol"},{"key":"918_CR33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198","journal-title":"J Psychiatr Res"},{"key":"918_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1972.tb07524.x","volume":"48","author":"Forssman","year":"1972","unstructured":"Forssman B, Kihlstrand S, Larsson LE (1972) Amantadine therapy in parkinsonism. Acta Neurol Scand 48(1):1\u201318","journal-title":"Acta Neurol Scand"},{"key":"918_CR35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"Freed","year":"2001","unstructured":"Freed CR, Greene PE, Breeze RE, et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med 344(10):710\u2013719","journal-title":"N Engl J Med"},{"key":"918_CR36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/syn.890190107","volume":"19","author":"Frohna","year":"1995","unstructured":"Frohna PA, Rothblat DS, Joyce JN, et al. (1995) Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Synapse 19(1):46\u201355","journal-title":"Synapse"},{"key":"918_CR37","first-page":"163","volume":"4","author":"Fuhrer","year":"1989","unstructured":"Fuhrer R, Rouillon F (1989) La version franciaise de l\u2019\u00e9chelle CES-D (Center for Epidemiologic Studies\u2013Depression scale). Description et traduction de l\u2019\u00e9chelle d\u2019auto-\u00e9valuation. Psychiatrie Biol 4:163\u2013166","journal-title":"Psychiatrie Biol"},{"key":"918_CR38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","volume":"178","author":"Gagnon","year":"1990","unstructured":"Gagnon C, Bedard PJ, Di Paolo T (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and\/or D-2 receptor agonists. Eur J Pharmacol 178(1):115\u2013120","journal-title":"Eur J Pharmacol"},{"key":"918_CR39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","volume":"107","author":"Giladi","year":"2000","unstructured":"Giladi N, Treves TA, Paleacu D, et al. (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson\u2019s disease. J Neural Transm 107(1):59\u201371","journal-title":"J Neural Transm"},{"key":"918_CR40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/jnnp.51.12.1498","volume":"51","author":"Girotti","year":"1988","unstructured":"Girotti F, Soliveri P, Carella F, et al. (1988) Dementia and cognitive impairment in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 51(12):1498\u20131502","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/syn.890140212","volume":"14","author":"Gnanalingham","year":"1993","unstructured":"Gnanalingham KK, Smith LA, Hunter AJ, et al. (1993) Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 14(2):184\u2013194","journal-title":"Synapse"},{"key":"918_CR42","first-page":"419","volume":"80","author":"Goetz","year":"1999","unstructured":"Goetz CG (1999) Hallucinations in Parkinson\u2019s disease: the clinical syndrome. Adv Neurol 80:419\u2013423","journal-title":"Adv Neurol"},{"key":"918_CR43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","volume":"58","author":"Goetz","year":"2001","unstructured":"Goetz CG, Burke PF, Leurgans S, et al. (2001) Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 58(2):209\u2013213","journal-title":"Arch Neurol"},{"key":"918_CR44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","volume":"57","author":"Goetz","year":"2001","unstructured":"Goetz CG, Leurgans S, Pappert EJ, et al. (2001) Prospective longitudinal assessment of hallucinations in Parkinson\u2019s disease. Neurology 57(11):2078\u20132082","journal-title":"Neurology"},{"key":"918_CR45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","volume":"50","author":"Goetz","year":"1998","unstructured":"Goetz CG, Pappert EJ, Blasucci LM, et al. (1998) Intravenous levodopa in hallucinating Parkinson\u2019s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50(2):515\u2013517","journal-title":"Neurology"},{"key":"918_CR46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"Goetz","year":"1995","unstructured":"Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology 45(4):669\u2013671","journal-title":"Neurology"},{"key":"918_CR47","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 43(11):2227\u20132229","journal-title":"Neurology"},{"key":"918_CR48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/ajp.139.11.1526","volume":"139","author":"Goetz","year":"1982","unstructured":"Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139(4):494\u2013497","journal-title":"Am J Psychiatry"},{"key":"918_CR49","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.51.3.811","volume":"51","author":"Goetz","year":"1998","unstructured":"Goetz CG, Vogel C, Tanner CM, et al. (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51(3):811\u2013814","journal-title":"Neurology"},{"key":"918_CR50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/jnnp.63.4.434","volume":"63","author":"Graham","year":"1997","unstructured":"Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 63(4):434\u2013440","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0006-8993(90)90440-M","volume":"514","author":"Graham","year":"1990","unstructured":"Graham WC, Clarke CE, Boyce S, et al. (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II.Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 514(1):103\u2013110","journal-title":"Brain Res"},{"key":"918_CR52","first-page":"703","volume":"60","author":"Greene","year":"1993","unstructured":"Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson\u2019s disease with clozapine. Adv Neurol 60:703\u2013706","journal-title":"Adv Neurol"},{"key":"918_CR53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/gps.930100608","volume":"10","author":"Haeske-Dewick","year":"1995","unstructured":"Haeske-Dewick HC (1995) Hallucinations in Parkinson\u2019s disease: characteristics and associated clinical features. Int J Geriatr Psychiatry 10:487\u2013495","journal-title":"Int J Geriatr Psychiatry"},{"key":"918_CR54","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/mds.10518","volume":"18","author":"Herzog","year":"2003","unstructured":"Herzog J, Volkmann J, Krack P, et al. (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson\u2019s disease. Mov Disord 18(11):1332\u20131337","journal-title":"Mov Disord"},{"key":"918_CR55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427\u2013442","journal-title":"Neurology"},{"key":"918_CR56","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 70(6):734\u2013738","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR57","first-page":"19","volume":"45","author":"Hornykiewicz","year":"1987","unstructured":"Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson\u2019s disease. Adv Neurol 45:19\u201334","journal-title":"Adv Neurol"},{"key":"918_CR58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","volume":"64","author":"Inzelberg","year":"1998","unstructured":"Inzelberg R, Kipervasser S, Korczyn AD (1998) Auditory hallucinations in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 64(4):533\u2013535","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR59","first-page":"S401","volume":"19","author":"Inzelberg","year":"2004","unstructured":"Inzelberg R, Ramirez A, Nisipeanu P, et al. (2004) Familial risk factors for hallucinations in Parkinson\u2019s disease. Mov Disord 19(Suppl 9):S401","journal-title":"Mov Disord"},{"key":"918_CR60","unstructured":"Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement Disorders, vol 2. Butterworth: London, pp 124\u2013165"},{"key":"918_CR61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jnnp.63.1.120","volume":"63","author":"Jimenez-Jimenez","year":"1997","unstructured":"Jimenez-Jimenez FJ, Orti-Pareja M, Gasalla T, et al. (1997) Cenesthetic hallucinations in a patient with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 63(1):120","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR62","first-page":"404","volume":"12","author":"Jurko","year":"1961","unstructured":"Jurko MF, Andy OJ (1961) Electrical and behavioral changes following thalamotomy. Surg Forum 12:404\u2013406","journal-title":"Surg Forum"},{"key":"918_CR63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","volume":"13","author":"Korczyn","year":"1998","unstructured":"Korczyn AD, Brooks DJ, Brunt ER, et al. (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 13(1):46\u201351","journal-title":"Mov Disord"},{"key":"918_CR64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","volume":"53","author":"Korczyn","year":"1999","unstructured":"Korczyn AD, Brunt ER, Larsen JP, et al. (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson\u2019s disease. The 053 Study Group. Neurology 53(2):364\u2013370","journal-title":"Neurology"},{"key":"918_CR65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988703256054","volume":"16","author":"Kurita","year":"2003","unstructured":"Kurita A, Ochiai Y, Kono Y, et al. (2003) The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson\u2019s disease. J Geriatr Psychiatry Neurol 16(3):184\u2013188","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"918_CR66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/brain\/106.2.257","volume":"106","author":"Lees","year":"1983","unstructured":"Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson\u2019s disease. Brain 106(Pt 2):257\u2013270","journal-title":"Brain"},{"key":"918_CR67","unstructured":"Lewy FH (1923) Die Lehre vom Tonus und die der Bewegung, ed. S Verlag, Berlin"},{"key":"918_CR68","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/WNL.50.6_Suppl_6.S33","volume":"50","author":"Lieberman","year":"1998","unstructured":"Lieberman A (1998) Managing the neuropsychiatric symptoms of Parkinson\u2019s disease. Neurology 50(6 Suppl 6): S33\u2013S38; discussion S44\u2013S48","journal-title":"Neurology"},{"key":"918_CR69","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.55.7.969","volume":"55","author":"Litvan","year":"1998","unstructured":"Litvan I, MacIntyre A, Goetz CG, et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55(7):969\u2013978","journal-title":"Arch Neurol"},{"key":"918_CR70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jnnp.64.2.178","volume":"64","author":"Mahieux","year":"1998","unstructured":"Mahieux F, Fenelon G, Flahault A, et al. (1998) Neuropsychological prediction of dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 64(2):178\u2013183","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","volume":"10","author":"Makoff","year":"2000","unstructured":"Makoff AJ, Graham JM, Arranz MJ, et al. (2000) Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson\u2019s disease. Pharmacogenetics 10(1):43\u201348","journal-title":"Pharmacogenetics"},{"key":"918_CR72","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356(9247):2031\u20132036","journal-title":"Lancet"},{"key":"918_CR73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","volume":"3","author":"McKeith","year":"2004","unstructured":"McKeith I, Mintzer J, Aarsland D, et al. (2004) Dementia with Lewy bodies. Lancet Neurol 3(1):19\u201328","journal-title":"Lancet Neurol"},{"key":"918_CR74","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.44.5.872","volume":"44","author":"McKeith","year":"1994","unstructured":"McKeith IG, Fairbairn AF, Bothwell RA, et al. (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 44(5):872\u2013877","journal-title":"Neurology"},{"key":"918_CR75","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"McKeith","year":"1996","unstructured":"McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113\u20131124","journal-title":"Neurology"},{"key":"918_CR76","first-page":"406","volume":"8","author":"Melamed","year":"1993","unstructured":"Melamed E, Zoldan J, Freidberg G (1993) Is hallucinosis in Parkinson\u2019s disease due to central serotonergic hyperactivity? Mov Disord 8:406\u2013407","journal-title":"Mov Disord"},{"key":"918_CR77","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-004-0209-9","volume":"111","author":"Merims","year":"2004","unstructured":"Merims D, Shabtai H, Korczyn AD, et al. (2004) Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson\u2019s disease. J Neural Transm 111 (10\u201311):1447\u20131453","journal-title":"J Neural Transm"},{"key":"918_CR78","unstructured":"Mojnes H (1949) Paralysis agitans. A clinical and genetic study. Acta Psychiatr Scand, p S54"},{"key":"918_CR79","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389","journal-title":"Br J Psychiatry"},{"key":"918_CR80","first-page":"51","volume":"3","author":"Morris","year":"1998","unstructured":"Morris SK, Olichney JM, Corey-Bloom J (1998) Psychosis in Dementia With Lewy Bodies. Semin Clin Neuropsychiatry 3(1):51\u201360","journal-title":"Semin Clin Neuropsychiatry"},{"key":"918_CR81","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"Moskovitz","year":"1978","unstructured":"Moskovitz C, Moses H 3rd, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135(6):669\u2013675","journal-title":"Am J Psychiatry"},{"key":"918_CR82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1532-5415.1996.tb00918.x","volume":"44","author":"Naimark","year":"1996","unstructured":"Naimark D, Jackson E, Rockwell E, et al. (1996) Psychotic symptoms in Parkinson\u2019s disease patients with dementia. J Am Geriatr Soc 44(3):296\u2013299","journal-title":"J Am Geriatr Soc"},{"key":"918_CR83","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002826-198205020-00003","volume":"5","author":"Nausieda","year":"1982","unstructured":"Nausieda PA, Weiner WJ, Kaplan LR, et al. (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5(2):183\u2013194","journal-title":"Clin Neuropharmacol"},{"key":"918_CR84","first-page":"S4","volume":"15","author":"Oertel","year":"2000","unstructured":"Oertel WH (2000) Pergolide versus L-dopa (PELMOPET). Mov Disord 15 (Suppl 3):S4","journal-title":"Mov Disord"},{"key":"918_CR85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM200107123450214","volume":"345","author":"Olanow","year":"2001","unstructured":"Olanow CW, Freeman T, Kordower J (2001) Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med 345(2):146; author reply 147","journal-title":"N Engl J Med"},{"key":"918_CR86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000050749","volume":"46","author":"Onofrj","year":"2001","unstructured":"Onofrj M, Thomas A, Iacono D, et al. (2001) Switch-over from tolcapone to entacapone in severe Parkinson\u2019s disease patients. Eur Neurol 46(1):11\u201316","journal-title":"Eur Neurol"},{"key":"918_CR87","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1002\/mds.10631","volume":"19","author":"Papapetropoulos","year":"2004","unstructured":"Papapetropoulos S, Gonzalez J, Lieberman A, et al. (2004) Dementia in Parkinson disease. Prevalence and clinical correlates from a population of brain donors. Mov Disord 19:S192","journal-title":"Mov Disord"},{"key":"918_CR88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, et al. (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord 14(1):117\u2013121","journal-title":"Mov Disord"},{"key":"918_CR89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jnnp.37.4.422","volume":"37","author":"Parkes","year":"1974","unstructured":"Parkes JD, Baxter RC, Marsden CD, et al. (1974) Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 37(4):422\u2013426","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR90","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","author":"Parkinson","year":"1997","unstructured":"Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Parkinson Study Group. Ann Neurol 42(5):747\u2013755","journal-title":"Ann Neurol"},{"key":"918_CR91","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson","year":"2000","unstructured":"Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931\u20131938","journal-title":"JAMA"},{"key":"918_CR92","first-page":"2","volume":"1","author":"Perry","year":"1990","unstructured":"Perry EK, Kerwin J, Perry RH, et al. (1990) Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of the Lewy body type. Dementia 1:2\u20134","journal-title":"Dementia"},{"key":"918_CR93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jnnp.53.1.88","volume":"53","author":"Perry","year":"1990","unstructured":"Perry EK, Kerwin J, Perry RH, et al. (1990) Visual hallucinations and the cholinergic system in dementia. J Neurol Neurosurg Psychiatry 53(1):88","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"918_CR94","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"Perry","year":"1990","unstructured":"Perry EK, Marshall E, Kerwin J, et al. (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454\u20131456","journal-title":"J Neurochem"},{"key":"918_CR95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1749-6632.1991.tb00217.x","volume":"640","author":"Perry","year":"1991","unstructured":"Perry EK, McKeith I, Thompson P, et al. (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson\u2019s disease, and Alzheimer\u2019s disease. Ann N Y Acad Sci 640:197\u2013202","journal-title":"Ann N Y Acad Sci"},{"key":"918_CR96","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/brain\/122.8.1449","volume":"122","author":"Piggott","year":"1999","unstructured":"Piggott MA, Marshall EF, Thomas N, et al. (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer\u2019s and Parkinson\u2019s diseases: rostrocaudal distribution. Brain 122(Pt 8)1449\u20131468","journal-title":"Brain"},{"key":"918_CR97","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00019052-200008000-00009","volume":"13","author":"Poewe","year":"2000","unstructured":"Poewe W, Hogl B (2000) Parkinson\u2019s disease and sleep. Curr Opin Neurol 13(4):423\u2013426","journal-title":"Curr Opin Neurol"},{"key":"918_CR98","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, et al. (2002) Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245\u2013255","journal-title":"Acta Neurol Scand"},{"key":"918_CR99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<120::AID-SYN5>3.0.CO;2-Y","volume":"36","author":"Pope-Coleman","year":"2000","unstructured":"Pope-Coleman A, Tinker JP, Schneider JS (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 36(2):120\u2013128","journal-title":"Synapse"},{"key":"918_CR100","first-page":"377","volume":"37","author":"Przedborski","year":"1991","unstructured":"Przedborski S, Jackson-Lewis V, Popilskis S, et al. (1991) Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgie 37(6):377\u2013382","journal-title":"Neurochirurgie"},{"key":"918_CR101","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1212\/WNL.45.3.432","volume":"45","author":"Rabey","year":"1995","unstructured":"Rabey JM, Treves TA, Neufeld MY, et al. (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson\u2019s disease. Neurology 45(3 Pt 1):432\u2013434","journal-title":"Neurology"},{"key":"918_CR102","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0014-2999(85)90101-3","volume":"113","author":"Raisman","year":"1985","unstructured":"Raisman R, Cash R, Ruberg M, et al. (1985) Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113(3):467\u2013468","journal-title":"Eur J Pharmacol"},{"key":"918_CR103","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484\u20131491","journal-title":"N Engl J Med"},{"key":"918_CR104","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16(6):1171\u20131174","journal-title":"Mov Disord"},{"key":"918_CR105","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.10274","volume":"17","author":"Richard","year":"2002","unstructured":"Richard IH, Papka M, Rubio A, et al. (2002) Parkinson\u2019s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17(6):1161\u20131165","journal-title":"Mov Disord"},{"key":"918_CR106","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.870080203","volume":"8","author":"Rinne","year":"1993","unstructured":"Rinne JO, Laihinen A, Rinne UK, et al. (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson\u2019s disease. Mov Disord 8(2):134\u2013138","journal-title":"Mov Disord"},{"key":"918_CR107","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0022-510X(95)00137-Q","volume":"132","author":"Rinne","year":"1995","unstructured":"Rinne JO, Laihinen A, Ruottinen H, et al. (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson\u2019s disease: a PET study with [11C]raclopride. J Neurol Sci 132(2):156\u2013161","journal-title":"J Neurol Sci"},{"key":"918_CR108","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0006-8993(85)91441-6","volume":"359","author":"Rinne","year":"1985","unstructured":"Rinne JO, Rinne JK, Laakso K, et al. (1985) Dopamine D-1 receptors in the parkinsonian brain. Brain Res 359(1\u20132):306\u2013310","journal-title":"Brain Res"},{"key":"918_CR109","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2165\/00003495-199855001-00004","volume":"55","author":"Rinne","year":"1998","unstructured":"Rinne UK, Bracco F, Chouza C, et al. (1998) Early treatment of Parkinson\u2019s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):S23\u2013S30","journal-title":"Drugs"},{"key":"918_CR110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, et al. (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309\u20131314","journal-title":"Neurology"},{"key":"918_CR111","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.870120204","volume":"12","author":"Rioux","year":"1997","unstructured":"Rioux L, Frohna PA, Joyce JN, et al. (1997) The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 12(2):148\u2013158","journal-title":"Mov Disord"},{"key":"918_CR112","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1523\/JNEUROSCI.17-21-08491.1997","volume":"17","author":"Robinson","year":"1997","unstructured":"Robinson TE, Kolb B (1997) Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17(21):8491\u20138497","journal-title":"J Neurosci"},{"key":"918_CR113","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry 141(11):1356\u20131364","journal-title":"Am J Psychiatry"},{"key":"918_CR114","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","volume":"53","author":"Sanchez-Ramos","year":"1996","unstructured":"Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson disease. Arch Neurol 53(12):1265\u20131268","journal-title":"Arch Neurol"},{"key":"918_CR115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1212\/WNL.46.2.388","volume":"46","author":"Schenck","year":"1996","unstructured":"Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2):388\u2013393","journal-title":"Neurology"},{"key":"918_CR116","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1176\/ajp.107.12.901","volume":"107","author":"Schwab","year":"1950","unstructured":"Schwab RS, Fabing HD, Prichard JS (1950) Psychiatric symptoms and syndromes in Parkinson\u2019s disease. Am J Psychiatry 107:901\u2013907","journal-title":"Am J Psychiatry"},{"key":"918_CR117","first-page":"279","volume":"17","author":"Singer","year":"2002","unstructured":"Singer C, Uzcategui G, Lyons K, et al. (2002) Efficacy and tolerability of amantadine: a retrospective review of old and new indications at a tertiary referral center. Mov Disord 17(S5):279","journal-title":"Mov Disord"},{"key":"918_CR118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0166-4328(94)00157-B","volume":"67","author":"Steckler","year":"1995","unstructured":"Steckler T, Sahgal A (1995) The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 67(2):165\u2013199","journal-title":"Behav Brain Res"},{"key":"918_CR119","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00004714-199502001-00003","volume":"15","author":"Svensson","year":"1995","unstructured":"Svensson TH, Mathe JM, Andersson JL, et al. (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism (corrected). J Clin Psychopharmacol 15(1 Suppl 1):S11\u2013S18","journal-title":"J Clin Psychopharmacol"},{"key":"918_CR120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1212\/WNL.26.4.305","volume":"26","author":"Sweet","year":"1976","unstructured":"Sweet RD, McDowell FH, Feigenson JS, et al. (1976) Mental symptoms in Parkinson\u2019s disease during chronic treatment with levodopa. Neurology 26(4):305\u2013310","journal-title":"Neurology"},{"key":"918_CR121","first-page":"136","volume":"14","author":"Tanner","year":"1983","unstructured":"Tanner CM, Vogel C, Goetz CG (1983) Hallucinations in Parkinson\u2019s disease: a population study. Ann Neurol 14:136","journal-title":"Ann Neurol"},{"key":"918_CR122","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","volume":"355","author":"Wang","year":"2004","unstructured":"Wang J, Zhao C, Chen B, et al. (2004) Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson\u2019s disease. Neurosci Lett 355(3):193\u2013196","journal-title":"Neurosci Lett"},{"key":"918_CR123","unstructured":"Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised Manual, ed. P Corporation, Cleveland"},{"key":"918_CR124","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.410130304","volume":"13","author":"Whitehouse","year":"1983","unstructured":"Whitehouse PJ, Hedreen JC, White CL 3rd, et al. (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13(3):243\u2013248","journal-title":"Ann Neurol"},{"key":"918_CR125","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.52.1.10","volume":"52","author":"Wolters","year":"1999","unstructured":"Wolters EC (1999) Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10\u2013S13","journal-title":"Neurology"},{"key":"918_CR126","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/PL00007822","volume":"248","author":"Wolters","year":"2001","unstructured":"Wolters EC (2001) Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol 248(Suppl 3):S22\u2013S27","journal-title":"J Neurol"},{"key":"918_CR127","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"Zoldan","year":"1993","unstructured":"Zoldan J, Friedberg G, Goldberg-Stern H, et al. (1993) Ondansetron for hallucinosis in advanced Parkinson\u2019s disease. Lancet 341(8844):562\u2013563","journal-title":"Lancet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0918-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-005-0918-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0918-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:40:36Z","timestamp":1586320836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-005-0918-5"}},"subtitle":["From description to etiology"],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":127,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s00415-005-0918-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}